Scarica l'app Stockscreener
1.64
3.53%
-0.06
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.70
Aprire:
$1.7
Volume 24 ore:
895.05K
Relative Volume:
0.42
Capitalizzazione di mercato:
$123.06M
Reddito:
-
Utile/perdita netta:
$-40.33M
Rapporto P/E:
-0.9162
EPS:
-1.79
Flusso di cassa netto:
$-39.53M
1 W Prestazione:
+3.80%
1M Prestazione:
-13.23%
6M Prestazione:
-45.33%
1 anno Prestazione:
-62.73%
Intervallo 1D:
$1.64
$1.73
Intervallo di 1 settimana:
$1.56
$1.755
Portata 52W:
$1.35
$4.98
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Nome
Eledon Pharmaceuticals Inc
Settore
Industria
Telefono
949-238-8090
Indirizzo
19800 MACARTHUR BLVD., IRVINE
Confronta ELDN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
1.64 | 127.56M | 0 | -40.33M | -39.53M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-18 | Ripresa | H.C. Wainwright | Buy |
| 2025-01-28 | Iniziato | Guggenheim | Buy |
| 2022-05-13 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-03-23 | Iniziato | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Borsa (ELDN) Ultime notizie
Kidney Transplant Rejection Market on Track for Major Expansion by 2034, According to DelveInsight | GE Healthcare, Viela Bio, Eledon Pharma, Neovii Biotech, GlaxoSmithKline, Novartis, Medeor - Barchart.com
Kidney Transplant Rejection Market on Track for Major Expansion - openPR.com
Eledon Pharmaceuticals Inc Stock Analysis and ForecastPrice-to-Earnings Ratio Insights & Free Stock Index Interpretations - earlytimes.in
Midday Stock Roundup: Compass Diversified Falls 20% After Conference Call - Orange County Business Journal
Why Eledon Pharmaceuticals Inc. stock is favored by pension fundsQuarterly Portfolio Review & Daily Profit Focused Screening - Newser
How analysts revise price targets for Eledon Pharmaceuticals Inc. (2TK) stockRisk Management & High Conviction Trade Alerts - Newser
Published on: 2025-12-04 05:40:36 - Newser
Why Eledon Pharmaceuticals Inc. (2TK) stock could be top winnerJuly 2025 Movers & Daily Risk Controlled Trade Plans - Newser
Is Eledon Pharmaceuticals Inc. (2TK) stock attractive post correctionBond Market & Verified High Yield Trade Plans - Newser
Why Eledon Pharmaceuticals Inc. (2TK) stock stays on buy lists2025 Dividend Review & Fast Momentum Stock Entry Tips - Newser
Eledon Pharmaceuticals (ELDN) Stock Analysis Report | Financials & Insights - Benzinga
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference - The Manila Times
What drives Eledon Pharmaceuticals Inc stock priceInflation Impact on Stocks & Capital Growth Strategies - earlytimes.in
Midday Stock Roundup: Eledon Up 4.8% - Orange County Business Journal
FY2025 Earnings Forecast for ELDN Issued By Leerink Partnrs - MarketBeat
United StatesMintz Advises On Eledon Pharmaceuticals’ $50 Million Follow-on Offering - Mondaq
Eledon Shares Fall Nearly 50% After Phase 2 Results - Orange County Business Journal
What is Eledon Pharmaceuticals Inc (ELDN) Stock Return on Shareholders’ Capital? - setenews.com
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
How analysts rate Eledon Pharmaceuticals Inc. stock todayWeekly Risk Summary & Growth Focused Stock Pick Reports - newser.com
Eledon Pharmaceuticals Reports Q3 2025 Financial Results - MSN
Will Eledon Pharmaceuticals Inc. (2TK) stock test record highs in 20252025 Risk Factors & Long-Term Growth Portfolio Plans - newser.com
Is Eledon Pharmaceuticals Inc. (2TK) stock supported by strong fundamentalsJuly 2025 Closing Moves & High Return Stock Watch Alerts - newser.com
Eledon Pharmaceuticals (ELDN) Price Target Decreased by 14.93% to 8.33 - MSN
What technical patterns form on Eledon Pharmaceuticals Inc. (2TK) stock chartsWeekly Gains Report & Accurate Entry/Exit Alerts - newser.com
Is Eledon Pharmaceuticals Inc. (2TK) stock worth buying before Fed actionTrend Reversal & Free Safe Capital Growth Stock Tips - newser.com
Eledon Pharmaceuticals Inc. stock momentum explainedEarnings Beat & Free Community Consensus Stock Picks - newser.com
Can Eledon Pharmaceuticals Inc. (2TK) stock sustain margin levelsJuly 2025 EndofMonth & Capital Protection Trading Alerts - newser.com
Eledon’s transplant rejection drug shows promise in Phase I/II diabetes trial - Clinical Trials Arena
Visual trend scoring systems applied to Eledon Pharmaceuticals Inc.Weekly Profit Recap & AI Driven Price Forecasts - newser.com
Eledon Pharmaceuticals (ELDN) Reports Promising Trial Results fo - GuruFocus
Market reaction to Eledon Pharmaceuticals Inc.’s recent newsTrade Signal Summary & Safe Capital Investment Plans - newser.com
Eledon Pharmaceuticals Inc Azioni (ELDN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):